For localized information and support, would you like to switch to your country-specific website for {0}?
- Insights
- Hematopathology IHC/ISH solutions
Driving diagnostic certainty with Hematopathology IHC/ISH solutions
Hematological cancers vary significantly in both prognosis and aggressiveness, demonstrating a need for tools that assist pathologists in making confident diagnoses and helping to inform clinical decisions.1,2,3 We offer more than 60 cornerstone and novel ready-to-use IHC antibodies and ISH probes, which aid in diagnostics of lymphoma, leukemia, myeloma and other hematopoietic malignancies.
The robust and novel assays are supported by the innovative detection chemistry to deliver the high sensitivity and specificity you need from your assays. The ready-to-use reagents on the fully automated BenchMark IHC/ISH instruments, backed with workflow solutions, help reducing the time-to-results and resources needed with manual or semi-automated systems.
Contact us
Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.
Featured assays
...
Contributors
Roche Diagnostics
Roche Diagnostics is a division of Roche, developing and integrating diagnostic solutions that address today’s healthcare challenges while anticipating tomorrow’s needs. In more than 100 countries, we provide one of the industry’s most comprehensive in vitro diagnostics portfolios spanning molecular diagnostics, clinical chemistry and immunoassays, tissue diagnostics, Point of Care testing, patient self-testing, next-generation sequencing, laboratory automation and IT, as well as digital health and decision-support solutions.
Our articles are authored by Roche Diagnostics subject matter experts, drawing on collective expertise across multiple disciplines to provide reliable insights for healthcare professionals worldwide.
Explore articles from our community
?wid=384&hei=216&fmt=png-alpha&fit=crop,1&cropn=0.07,0,0.86,1)
?wid=384&hei=216&fmt=png-alpha&fit=crop,1&cropn=0.07,0,0.86,1)
No insights found
Contact us
Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.
References
- Tilly H, Gomes da Silva M, Violo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, Andre M, Johnson PW, Pfreudschuh M, Ladetto M. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Haematological Malignancies, Vol 26:S5, 2015.
- Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamo A, Zucca E. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Annals of Oncology, Vol 27:12, 2016.
- Zucca E, Arcaini L, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, Vol 31:1. 2020.